V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

Haemonetics Executive Compensation (FY26)

HAE · Executive and director compensation, fiscal 2023 to 2026
Data as of September 7, 2026Latest filing (8-K): July 28, 2026
370 figures on this page: 358 cited to the filing that reported them, 12 calculated from figures it prints. See the citations
The disclosed peer group includes Avanos Medical, Inc., Azenta, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corp. and Bruker Corporation, among others. Christopher Simon was paid $12,044,701 in total compensation as President and Chief Executive Officer for fiscal 2026, and Simon's total was 12.3% higher than the $10,722,488 reported for fiscal 2025. For fiscal 2026, the company reported a chief executive pay ratio of 216:1, against median employee compensation of $55,645. For fiscal 2026, shareholders backed the say-on-pay proposal with 98.6% of votes cast for or against in favor at the meeting held July 24, 2026.
Chief executive, fiscal 2026
◇
Christopher Simon
Latest say-on-pay support
=
July 24, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2025 to fiscal 2026
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Christopher Simon: $10,722,488 → $12,044,701 (12.3% higher)
Say-on-pay support: 98.7% → 98.6% (0.1 points lower)
CEO pay ratio: 196:1 → 216:1 (10.2% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Haemonetics' chief executive and what were they paid?
Christopher Simon was paid $12,044,701 in total compensation as President and Chief Executive Officer for fiscal 2026. Simon's total was 12.3% higher than the $10,722,488 reported for fiscal 2025.
What was Haemonetics' say-on-pay result?
For fiscal 2026, shareholders backed the say-on-pay proposal with 98.6% of votes cast for or against in favor at the meeting held July 24, 2026.
Which companies are in Haemonetics' peer group?
The disclosed peer group includes Avanos Medical, Inc., Azenta, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corp. and Bruker Corporation, among others.
What is Haemonetics' chief executive pay ratio?
For fiscal 2026, the company reported a chief executive pay ratio of 216:1, against median employee compensation of $55,645.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Simon
President and Chief Executive Officer
◇—◇◇◇—◇◇
James D'Arecca
Executive Vice President, Chief Financial Officer
◇◇◇◇◇—◇◇
Michelle Basil
Executive Vice President, General Counsel
◇—◇◇◇—◇◇
Josep Llorens
Executive Vice President, Global Manufacturing and Supply Chain
◇—◇◇◇—◇◇
Anila Lingamneni
Executive Vice President, Chief Technology Officer
◇—◇◇◇—◇◇
William Burke
Executive Vice President, Chief Financial Officer (through April 11, 2022)
◇◇——◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Simon
President and Chief Executive Officer
◇—◇◇◇—◇◇
James D'Arecca
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Michelle Basil
Executive Vice President, General Counsel
◇—◇◇◇—◇◇
Anila Lingamneni
Executive Vice President, Chief Technology Officer
◇—◇◇◇—◇◇
Josep Llorens
Executive Vice President, Global Manufacturing and Supply Chain
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Simon
President and Chief Executive Officer
◇—◇◇◇—◇◇
James D'Arecca
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Michelle Basil
Executive Vice President, General Counsel
◇—◇◇◇—◇◇
Roy Galvin
Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
Stewart Strong
Former President, Global Hospital
Departed during or after this year
◇—◇◇◇—◇◇
Fiscal 2026
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Simon
President and Chief Executive Officer
◇—◇◇◇—◇◇
James D'Arecca
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Michelle Basil
Executive Vice President, General Counsel
◇—◇◇◇—◇◇
Frank Chan
Executive Vice President, Chief Operating Officer
◇◇◇◇◇—◇◇
Roy Galvin
Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2026
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher A. SimonPSU◇◇◇—◇—◇
Christopher A. SimonOPTION◇——◇—◇◇
Frank W. ChanOPTION◇——◇—◇◇
Frank W. ChanPSU◇◇◇—◇—◇
James C. D'AreccaOPTION◇——◇—◇◇
James C. D'AreccaPSU◇◇◇—◇—◇
Michelle L. BasilPSU◇◇◇—◇—◇
Michelle L. BasilOPTION◇——◇—◇◇
Roy GalvinOPTION◇——◇—◇◇
Roy GalvinPSU◇◇◇—◇—◇
Fiscal 2023, 2024, 2025 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2026 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
James D'AreccaOption◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Michelle BasilRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Roy GalvinRSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Frank ChanRSU◇◇——
Option◇—◇—
RSU◇◇——
Christopher SimonRSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Roy Galvin
Executive Vice President, Chief Commercial Officer · Severance agreement
Severance multiple◇
Severance base◇
Benefits continuation◇
Clawback◇
Frank Chan
Executive Vice President, Chief Operating Officer · Severance agreement
Severance multiple◇
Severance base◇
Benefits continuation◇
Michelle Basil
Executive Vice President, General Counsel · Severance agreement
Severance multiple◇
Severance base◇
Benefits continuation◇
Clawback◇
James D'Arecca
Executive Vice President, Chief Financial Officer · Severance agreement
Severance multiple◇
Severance base◇
Benefits continuation◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2026
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ellen M. Zane
Board chair
◇◇————◇
Lloyd E. Johnson
◇◇————◇
Robert E. Abernathy
◇◇————◇
Claire Pomeroy
◇◇————◇
Charles J. Dockendorff
◇◇————◇
Michael J. Coyle
◇◇————◇
Diane M. Bryant
◇◇————◇
Mark W. Kroll
◇◇————◇
Christopher A. Simon served on the board in fiscal 2026 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.
Stock ownership guideline: Our share ownership guidelines;

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2026
  • Avanos Medical, Inc. AVNS
  • Azenta, Inc. AZTA
  • Bio-Rad Laboratories, Inc. BIO
  • Bio-Techne Corp. TECH
  • Bruker Corporation BRKR
  • CONMED Corporation CNMD
  • Globus Medical, Inc. GMED
  • ICU Medical, Inc. ICUI
  • Insulet Corporation PODD
  • Integra LifeSciences IART
  • LivaNova PLC LIVN
  • Masimo Corporation MASI
  • Merit Medical Systems, Inc. MMSI
  • QuidelOrtho Corporation QDEL
  • Revvity, Inc. RVTY
  • Teleflex Incorporated TFX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2026July 24, 2026=◇◇◇
2025July 24, 2025=◇◇◇
2024July 24, 2025=◇◇◇
2023July 25, 2024=◇◇◇
2022August 4, 2023=◇◇◇
2021August 5, 2022=◇◇◇
2020August 6, 2021=◇◇◇
2019July 21, 2020=◇◇◇
2018July 25, 2019=◇◇◇
2017July 26, 2018=◇◇◇
2016July 27, 2017=◇◇◇
2015July 21, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Haemonetics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Haemonetics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Haemonetics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Haemonetics' disclosed peer group is defensible, who names Haemonetics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
370 figures on this page: 358 cited to the filing that reported them, 12 calculated from figures it prints.
358 cited to the filing
12 calculated from the filing

Documents cited

  1. 0000313143-26-000095
  2. 0000313143-26-000074
    CEO Pay Ratio · CURRENT OVERVIEW OF OUTSTANDING EQUITY AWARDS · DIRECTOR COMPENSATION TABLE FOR FISCAL YEAR ENDED MARCH 28, 2026 · Director Compensation · and 4 more sections
  3. 0000313143-25-000047
  4. 0000313143-25-000041
    SUMMARY COMPENSATION TABLE
  5. 0000313143-24-000044
  6. 0000313143-24-000040
    SUMMARY COMPENSATION TABLE
  7. 0000313143-23-000037
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000313143-23-000028
    SUMMARY COMPENSATION TABLE
  9. 0000313143-22-000045
  10. 0000313143-21-000037
  11. 0000313143-20-000058
  12. 0000313143-19-000035
  13. 0000313143-18-000046
  14. 0000313143-17-000044
    Employment Agreement · Exhibit
  15. 0000313143-17-000028
  16. 0000313143-16-000136
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Haemonetics executive compensation, FY2023–FY2026.” https://intel.velarion.ai/comp/HAE (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Haemonetics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Haemonetics discloses

The companies named in HAE's own disclosed peer group.

Avanos Medical, Inc.Azenta, Inc.Bio-Rad Laboratories, Inc.Bio-Techne Corp.Bruker CorporationCONMED CorporationGlobus Medical, Inc.ICU Medical, Inc.Insulet CorporationIntegra LifeSciencesLivaNova PLCMasimo CorporationMerit Medical Systems, Inc.Revvity, Inc.Teleflex Incorporated

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy